Clinical and pharmacological approaches for treatment of bronchial asthma: Flashcards
define bronchial asthma
chronic, inflammatory disease of the respiratory tract, which is characterized by bronchial hyperreactivity and respiratory obstruction.
what causes intermittent airway narrowing in asthma
⦁ bronchoconstriction,
⦁ congestion or edema of bronchial mucosa,
⦁ mucus,
⦁ or a combination of these
classification of asthma
extrinsic- atopic
intrinsic-non atopic
specific - occupatio/ aspirin
symptomatic classification
intermittent
mild persistant
moderate persistant
severe persistent
intermittent asthma
one day attack a week
one night attack per month
mild persistent
more than one day attack a week but less than one attack per day
night attacks 2x / month
moderate persistent
everyday attacks
night attack 1x a week
severe persistent
everyday frequent excacerbations
frequent night attacks
limited physical activity
what is GINA
GLOBAL INITIATIVE for ASTHMA maNAGEment
stepwise approach to the management of bronchial asthma
goals in rx of asthma
⦁ Avoid troublesome symptoms during day and night;
⦁ Need little or no reliever medication;
⦁ Have productive, physically active lives;
⦁ Have normal or near normal lung function;
⦁ Avoid serious asthma flare-ups (exacerbations, or attacks);
drug classificatino for asthma
Relievers – used for the treatment of the asthmatic attack:
Controllers – used to control the symptoms:
list the relievers
⦁ Short-acting β2 agonists (SABA).
⦁ Short-acting antimuscarinics.
⦁ Short-acting phosphodiesterase inhibitors.
⦁ Systemic corticosteroids
Controllers
⦁ Long-acting β2 agonists (LABA) ⦁ Inhaled corticosteroids ⦁ L-acting antimuscarinics ⦁ L-acting phosphodiesterase inhibitors ⦁ Leucotrien modifiers and mast cell stabilizers
devices used in asthma
Metered Dose Inhaler (MDI) : Spacers can help patients who have difficulty with inhaler use and can reduce potential for adverse effects from medication.
Nebulizer : Machine produces a mist of the medication/ Used for small children or for severe asthma episodes
Dry powder inhalers (DPI) : Single dose/ Multiple doses
Inhaled
step waise approach to bronchial asthma guidline
step 1: intermittent
step2: mild persistent
step3: moderate persistent
step 4: severe persistent
step 1
daily therapy : none
supplementary therapy: none
step 2
daily therapy; Low dose ICS
supplementary therapy:
leukotriene antagonise/ slow release theophyline
step 3;
daily therapy;
MOD ICS + LABA
supplementary therapy:
mod ICS + slow release thophyline
step 4
daily therapy;
high dose ICS + LABA
supplementary therapy: more than one slow release theophyline leukkotriene antagonist ige antibodies
effects of CS on asthma
⦁ Suppress inflammatory response to Ag-Ab reaction
Reduced bronchial hyperreactivity
effects of ICS on bronchi
Do Not have direct bronchodilating effect but potentiates the effects of β2-adrenergic agonists.
effects of CS on PT
⦁ Ιncrease lung function;/
reduce symptoms;/ improve quality of life;/ reduce the risk of exacerbations;/
reduce asthma-related hospitalizations and death.
how often must CS be taken
every day to controll inflammation even if symptoms are absent
list the inhaled corticosteroids
⦁ Beclomethasone (Becotide) – spray 50 µg
⦁ Fluticasone (Flixotide) -spray 25 µg
⦁ Budesonide (Pulmicort) - inhalation powder - 100 µg
ICS ADR’S
rare
⦁ Oropharyngeal candidiasis
⦁ Dysphonia.
indication of short term systemic corticosteroids rx
early in the treatment of severe acute exacerbation for 5-7 days